Time Reveals the Truth! What Treatments for COVID-19 Were Quickly Abandoned, and Which Methods, Contrary to Popular Belief, Are Still Flourishing?

Q3 Medicine
Joseph John Bevelacqua, Abdolkarim Ghadimi-Moghadam, Seyed Alireza Mortazavi, Abdollah Jafarzadeh, Masoud Haghani, Azim Kaveh-Ahangar, Ali Ghadimi-Moghadam
{"title":"Time Reveals the Truth! What Treatments for COVID-19 Were Quickly Abandoned, and Which Methods, Contrary to Popular Belief, Are Still Flourishing?","authors":"Joseph John Bevelacqua, Abdolkarim Ghadimi-Moghadam, Seyed Alireza Mortazavi, Abdollah Jafarzadeh, Masoud Haghani, Azim Kaveh-Ahangar, Ali Ghadimi-Moghadam","doi":"10.31661/jbpe.v0i0.2206-1514","DOIUrl":null,"url":null,"abstract":"<p><p>During the early days of the COVID-19 pandemic, low dose radiation therapy (LDRT) was proposed as a potentially effective treatment method. To minimize potential toxicity, the initial treatment approach involved a few mGy of adapting radiation followed by a single 250 mGy whole lung challenging dose. However, antiviral drugs were also introduced as a promising treatment option, which were thought to have the potential to revolutionize the management of the crisis. Despite early warnings, many physicians did not fully consider the key point that, in contrast with LDRT, antiviral drug treatments can result in strong selective pressure on the virus. This can lead to the emergence of new SARS-CoV-2 variants, a phenomenon that can have serious global consequences. After more than two years, the truth has been revealed the WHO Guideline Development Group has advised against the use of remdesivir, a widely used antiviral medication, for COVID-19. Meanwhile, a growing body of evidence suggests that LDRT can be a promising, low-risk approach for avoiding or delaying invasive respiratory support in COVID-19 patients. Although there is substantial supporting documentation, more high-quality, controlled, and randomized double-blind clinical trials are needed to further investigate the efficacy and potential therapeutic mechanisms of LDRT for COVID-19.</p>","PeriodicalId":38035,"journal":{"name":"Journal of Biomedical Physics and Engineering","volume":"14 6","pages":"599-606"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11668932/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biomedical Physics and Engineering","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31661/jbpe.v0i0.2206-1514","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

During the early days of the COVID-19 pandemic, low dose radiation therapy (LDRT) was proposed as a potentially effective treatment method. To minimize potential toxicity, the initial treatment approach involved a few mGy of adapting radiation followed by a single 250 mGy whole lung challenging dose. However, antiviral drugs were also introduced as a promising treatment option, which were thought to have the potential to revolutionize the management of the crisis. Despite early warnings, many physicians did not fully consider the key point that, in contrast with LDRT, antiviral drug treatments can result in strong selective pressure on the virus. This can lead to the emergence of new SARS-CoV-2 variants, a phenomenon that can have serious global consequences. After more than two years, the truth has been revealed the WHO Guideline Development Group has advised against the use of remdesivir, a widely used antiviral medication, for COVID-19. Meanwhile, a growing body of evidence suggests that LDRT can be a promising, low-risk approach for avoiding or delaying invasive respiratory support in COVID-19 patients. Although there is substantial supporting documentation, more high-quality, controlled, and randomized double-blind clinical trials are needed to further investigate the efficacy and potential therapeutic mechanisms of LDRT for COVID-19.

时间揭示真相!哪些治疗COVID-19的方法很快就被放弃了,哪些与普遍看法相反的方法仍然盛行?
在COVID-19大流行的早期,低剂量放射治疗(LDRT)被提出作为一种潜在的有效治疗方法。为了尽量减少潜在的毒性,最初的治疗方法包括几毫戈瑞的适应性辐射,然后是250毫戈瑞的单次全肺激发剂量。然而,抗病毒药物也被作为一种有希望的治疗选择,被认为有可能彻底改变危机的管理。尽管有早期预警,但许多医生没有充分考虑到一个关键点,即与LDRT相比,抗病毒药物治疗可对病毒产生强烈的选择性压力。这可能导致新的SARS-CoV-2变体的出现,这种现象可能会产生严重的全球后果。两年多后,真相大白。世卫组织指南制定小组建议不要使用广泛使用的抗病毒药物瑞德西韦治疗COVID-19。与此同时,越来越多的证据表明,LDRT可能是一种有希望的低风险方法,可避免或延迟COVID-19患者的有创呼吸支持。尽管已有大量支持文献,但仍需要更多高质量、对照、随机的双盲临床试验来进一步研究LDRT治疗COVID-19的疗效和潜在的治疗机制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Biomedical Physics and Engineering
Journal of Biomedical Physics and Engineering Medicine-Radiology, Nuclear Medicine and Imaging
CiteScore
2.90
自引率
0.00%
发文量
64
审稿时长
10 weeks
期刊介绍: The Journal of Biomedical Physics and Engineering (JBPE) is a bimonthly peer-reviewed English-language journal that publishes high-quality basic sciences and clinical research (experimental or theoretical) broadly concerned with the relationship of physics to medicine and engineering.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信